OKYO

OKYO Pharma Limited · NASDAQ

Sector Health Technology
Industry Biotechnology
Website okyopharma.com
Employees(FY) 8
ISIN GG00BMFG5F62

Performance

-1.33%

1W

+5.71%

1M

+3.5%

3M

-16.38%

6M

-16.38%

YTD

-30.52%

1Y

Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of OKYO 2024-05-03

Overview:

In analyzing the technical indicators for OKYO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.

Trend Anal...

See more ...

Recent News & Updates

2024-05-07 19:00
OKYO Pharma Announces Participation in May 2024 Investor Conferences(Globenewswire)
2024-04-29 19:00
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)(Globenewswire)
2024-04-08 07:00
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024(Globenewswire)
2024-04-01 19:00
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery(Globenewswire)
2024-03-21 19:00
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101(Globenewswire)
2024-03-20 19:00
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial(Globenewswire)
2024-03-19 19:00
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event(Globenewswire)
2024-02-08 18:00
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain(Globenewswire)
2024-01-30 18:00
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board(Globenewswire)
2024-01-07 18:00
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease(Globenewswire)
2024-01-04 20:30
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024(Globenewswire)
2023-12-03 18:00
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit(Globenewswire)
2023-10-30 19:00
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction(Globenewswire)
2023-10-08 19:00
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP)(Yahoo Finance)
2023-10-04 19:00
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ('DED')(Globenewswire)
2023-09-14 19:00
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares(Yahoo Finance)
2023-09-13 21:15
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares(Yahoo Finance)
2023-09-13 20:45
OKYO Pharma Limited Announces Withdrawal of Public Offering(Yahoo Finance)
2023-09-13 04:05
OKYO Pharma Announces Public Offering of Ordinary Shares(Yahoo Finance)
2023-09-07 19:00
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease(Yahoo Finance)
2023-08-29 19:00
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (DED)(Yahoo Finance)
2023-08-28 19:00
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule(Yahoo Finance)
2023-08-14 21:00
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023(Yahoo Finance)
2023-07-30 14:18
OKYO Pharma Limited Announces Withdrawal of Public Offering(Yahoo Finance)
2023-07-28 05:25
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares(Yahoo Finance)
2023-07-28 05:05
OKYO Pharma Limited Receives Nasdaq Deficiency Notice(Yahoo Finance)
2023-07-27 19:01
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (NCP) Following Announcement of Clinical Trial Agreement with Tufts Medical Center(Yahoo Finance)
2023-07-26 23:30
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer(Yahoo Finance)
2023-06-05 21:30
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease(Yahoo Finance)
2023-05-10 19:00
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform(Yahoo Finance)

Page 1 of 2

previousnext